KRAS mutations are associated with specific morphologic features in colon cancer

Journal of Clinical Gastroenterology

Volumn 47, Issue 6, 2013, Pages 509-514

  Gunal, Armagan ^a   Hui, Pei ^b   Kilic, Selim ^a   Xu, Ruliang ^c   Jain, Dhanpat ^b   Mitchell, Kisha ^b   Robert, Marie ^b   Kenney, Barton ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma; Colon; KRAS; Morphology; Mutation

Indexed keywords

K RAS PROTEIN;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER MORPHOLOGY; COLON ADENOCARCINOMA; COLON CANCER; COLON RESECTION; COLON SURGERY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES;

EID: 84879880574     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182703030     Document Type: Article

References (29)

1. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90: 675-684.
2. Andreyev HJN, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study. Br J Cancer. 2001;85: 692-696.
3. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000;9: 1193-1197.
4. Javle M, Hsueh CT. Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol. 2009;2:9.
5. Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158: 527-535.
6. Dillon DA, Johnson CC, Topazian MD, et al. The utility of Ki-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasms. Cancer J. 2000;6: 294-301.
7. Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol. 2009;7: 45-53.
8. Baynes RD, Gansert J. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther. 2009;16: 554-561.
9. Keller JW, Franklin JL, Graves-Deal R, et al. Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. J Cell Physiol. 2007;210: 740-749.
10. van Krieken JHJM, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453: 417-431.
11. Vogelstein B, Fearon ER, Stanley SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med. 1998;319: 525-532.
12. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26: 1626-1634.
13. Lievre A, Bachet JB, Le CD, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66: 3992-3995.
14. Greenson JK, Huang SC, Herron C. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol. 2009;33: 126-133.
15. Song GA, Deng G, Bell I, et al. Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol. 2005;26: 745-750.
16. Tanaka H, Deng G, Matsuzaki K, et al. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer. 2006;118: 2765-2771.
17. Sugai T, Habano W, Jiao YF, et al. Analysis of molecular alterations in left and right-sided colorectal carcinomas reveals distinct pathways of carcinoma. J Mol Diagn. 2006;8: 193-201.
18. Bleeker WA, Hayes VM, Karrenbeld A, et al. Impact of KRAS and TP53 mutations on survival in patients with left and right sided Dukes' C colon cancer. Am J Gastroenterol. 2000;95: 2953-2957.
19. Yantiss RK, Goodarzi M, Zhou XK, et al. Clinical, pathologic and molecular features of early onset colorectal carcinoma. Am J Surg Pathol. 2008;33: 572-582.
20. Chang DT, Pai RK, Rybicki LA, et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012;25: 1128-1139.
21. Olschwang S, Slezak P, Roze M, et al. Somatically acquired genetic alterations in flat colorectal neoplasias. Int J Cancer. 1998;77: 366-369.
22. Wyk RV, Slezak P, Hayes VM, et al. Somatic mutations of APC, KRAS and TP53 genes in nonpolypoid colorectal adenomas. Genes Chromosomes Cancer. 2000;27: 202-208.
23. Uronis JM, Herfarth HH, Rubinas TC, et al. Flat colorectal cancers are genetically determined and progress to invasion without going through a polypoid stage. Cancer Res. 2007;67: 11594-11600.
24. Chen H, Lefferts JA, Schwab MC, et al. Correlation of polypoid colorectal adenocarcinoma with pre-existing adenomatous polyps and KRAS mutation. Cancer Genet. 2011;204: 245-251.
25. Russo A, Bazan B, Agnese V, et al. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol. 2005;16(suppl 4):iv44-iv49.
26. Shono Y, Tanimura H, Iwahashi M, et al. Specific T cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers. Br J Cancer. 2003;88: 530-536.
27. Fossum B, Breivik J, Meling GI, et al. A Ki-ras 13 GLY-ASP mutation is recognized by HLA-DQ7 restricted T-cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? Int J Cancer. 1994;58: 506-511.
28. Velho S, Moutinho C, Cirnes L, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer. 2008;8:255.
29. Redston M. Epithelial neoplasms of the large intestine. In: Odze RD, Goldblum JR, eds. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2009: 597-637.